A year-long extension of the landmark PURPOSE 1 and PURPOSE 2 trials has confirmed that lenacapavir, the twice-yearly injectable sold as Yeztugo, remains a highly effective shield against HIV. Across the extended follow-up period, researchers recorded just a single new infection among participants, reinforcing the drug’s standing as one of the most promising tools yet in HIV prevention.
The results matter because adherence has long been the Achilles heel of daily oral PrEP pills, which require consistent, near-perfect use to stay effective. A twice-a-year injection sidesteps that challenge almost entirely, offering a level of convenience that could make sustained protection realistic for far more people, including those who have struggled to stick to daily regimens in the past.
Health experts say the durability of lenacapavir’s protection could prove pivotal in closing persistent gaps in HIV prevention across different communities. By reducing the burden of daily pill-taking, the drug may widen access to effective prophylaxis and push the broader goal of curbing new HIV infections closer within reach.
Source: medpagetoday.com
